[1] PAOLA R, GIULIA M, SERENA C, et al.Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics[J].Medicina,2021,57(9):916-929. [2] Clerc O F, Cuddy S A M, Michael J, et al. Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain Amyloidosis[J].medRxiv: the preprint server for health sciences,2023,2023:23296572. [3] 路瑾. 系统性轻链型淀粉样变性的诊治进展[J].临床血液学杂志,2021,34(3):205-209. [4] 洪伊,张媛媛,李真,等.系统性轻链型淀粉样变性发病机制及诊治进展[J].肾脏病与透析肾移植杂志,2023,32(2):156-162. [5] MEILAN C, JUNRU L, XIAOHONG W, et al.Diagnosis for Chinese patients with light chain amyloidosis: a scoping review.[J].Annals of medicine,2023,55(1):2227425. [6] SIDANA S, LARSON D P, GREIPP P T, et al.IgM AL amyloidosis: delineating disease biology and outcomes with clinical,genomic and bone marrow morphological featuresl[J].Leukemia,2020,34(5):1373-1382. [7] WECHALEKAR A D, CHAKRABORTY R, LENTZSCH S.Systemic Amyloidosis due to Low-Grade Lymphomal[J].Hematol Oncol Clin North Am,2020,34(6):1027-1039. [8] 蔡真,何冬花.如何诊断和治疗系统性轻链型肾淀粉样变性[J].肾脏病与透析肾移植杂志,2021,30(6):549-550. [9] YANG L, NELSON L, JIN L.Systemic light chain amyloidosis: the hope for a cure[J].Science Bulletin,2023,68(22):2678-2681. [10] 戈程,李佳月,刘博罕,等.心肌淀粉样变性临床特点及远期预后的影响因素[J].中华老年多器官疾病杂志,2020,19(6):405-409. [11] RUSNĖ J, VALDAS P, SIGITA A, et al.Electrocardiographic left ventricular strain pattern, ST-segment depression and atrial fibrillation at the time of diagnosis of systemic light chain amyloidosis: Incidence and clinical significance[J].Journal of Electrocardiology,2021,68:157-163. [12] MEILAN C, JUNRU L, XIAOHONG W, et al.Diagnosis for Chinese patients with light chain amyloidosis: a scoping review[J].Annals of medicine,2023,55(1):2227425. [13] 中国系统性轻链型淀粉样变性协作组,国家肾脏疾病临床医学研究中心,国家血液系统疾病临床医学研究中心.系统性轻链型淀粉样变性诊断和治疗指南(2021年修订)[J].中华医学杂志,2021,101(22):1646-1656. [14] VAISHALI S, MARIO B, MORIE G, et al.Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines[J].Amyloid,2021,29(1):1-7. [15] RAJSHEKHAR C, PAOLO M, GIOVANNI P, et al.Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies[J].The Lancet. Haematology,2023,10(11):e936-e940. [16] DISPENZIERI A, GERTZ M A, KYLE R A, et al.Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation[J].Blood,2004,104(6):1881-1887. [17] KUMAR S, DISPENZIERI A, LACY M Q, et al.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements[J].Journal of clinical oncology,2012,30(9):989-995. [18] LI T, HUANG X, WANG Q, et al.A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvementl[J].Br J Haematol,2019,187(4):459-469. [19] BASSET M, MILANI P, FERRETTI V V, et al.Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients[J].Clin Chem Lab Med,2022,60(3):386-393. [20] LILLENESS B, RUBERG F L, MUSSINELLI R, et al.Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis[J].Blood,2019,133(3):215-223. [21] GEORGIA T, DESPINA F, ANASTASIOS K, et al.Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis[J].Amyloid,2022,30(2):1-8. |